On January 8, 2026 32 Biosciences, a gastrointestinal (GI)-focused biotechnology company pioneering gut mucosal-immune science to prevent and treat GI diseases, reported that it will officially launch its $40 million Series A financing during the 2026 J.P. Morgan Healthcare Conference (January 12–15, 2026).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Series A financing is intended to advance CS-0003, a first-in-class Mucosal-Immune Modulator (MIM) designed to buffer the GI tract by coating and protecting the mucosal barrier, suppressing bacterial virulence, and modulating the mucosal-immune system. The lead indication is prevention of gastrointestinal surgical site infections (GI SSI), with potential expansion into inflammatory bowel disease (IBD) and prevention of colon cancer recurrence, where mucosal barrier dysfunction and immune dysregulation play a central role.
"Launching our Series A at JPM is a key step as we advance CS-0003 into the clinic and build our GB discovery platform," said Peter Farmakis, Chairman & Chief Executive Officer of 32 Biosciences. "We’re restoring and protecting the gut mucosal-immune system—an overlooked but central driver of surgical outcomes and chronic disease—with the goal of meaningfully improving outcomes for patients facing serious GI disease."
A differentiated therapeutic and platform built around gut mucosal-immune biology
32 Biosciences is advancing a first-in-class therapeutic and a metabolomics-based discovery platform to identify and enable new approaches to restore and protect the GI mucosal-immune system across multiple high-unmet-need indications, starting with GI surgical site infection.
CS-0003, a first-in-class Mucosal-Immune Modulator (MIM) being advanced through IND-enabling studies and into Phase I clinical development, with plans to advance through Phase II efficacy in GI SSI; and
GB: the GI Discovery Platform, a metabolomics-based platform designed to quantify signatures of gut mucosal function and host-microbe interactions to enable therapeutic discovery, development, and future clinical decision support.
Together, CS-0003 and GB are designed to support a differentiated pipeline across high-unmet-need GI indications.
Series A launch at JPM
At the J.P. Morgan Healthcare Conference, 32 Biosciences will meet with prospective investors and strategic partners to discuss the Series A financing and its planned use of proceeds, including advancing CS-0003 into the clinic and progressing GB partnerships and validation.
(Press release, 32 Biosciences, JAN 8, 2026, View Source [SID1234661884])